Stocks analysis

Analysis for UHS

  • 📈 Growth — 22/30
  • 💰 Profitability — 12/20
  • 🏦 Financial Health — 14/20
  • 💵 Valuation — 12/20
  • ⚠️ Risk — 7/10
Overall Score: 63/100

Summary:


📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $4.10B to about $4.64B, a net gain of roughly $0.54B (~13%). Net income improved from about $317M to roughly $365M, with a notable $448M peak in 2025-Q4 before a modest normalization in 2026-Q2, indicating a positive but uneven trajectory.

💰 Margins & Cash Flow

Margins have been in the low-to-mid single digits when viewed as net income yield (roughly 7–10%), with late-2025 shows of higher margin (around 10–13% proxy). Operating cash flow remained positive across quarters, peaking near $575M in 2025-Q4 and remaining strong in 2026-Q2 (~$443M). Investing cash flow was consistently negative; financing activity fluctuated, creating some quarterly cash swings.

🛡️ Balance Sheet & Liquidity

Total assets run ~$14–15B with liabilities near $7–8B and equity around $6–7B, yielding a modestly leveraged profile. Current ratio hovers around 1.1–1.2 in tested quarters. Positive operating cash flow supports debt service capacity, while long-term debt sits around $4.6–$4.9B.

⚠️ Key Drivers & Risks

  • Drivers: Stable inpatient demand and mix, with scale advantages in hospital operations.
  • Risks: Regulatory/reimbursement changes and rising labor costs; valuation sensitivity to volume and margin fluctuations.